CMD22 Capital Markets Day

10 Commercial execution and innovation NASH and Alzheimer's disease Novo NordiskⓇ Evoke and evoke+ trials are ongoing with expected completion in 2025 evoke and evoke+ trials have been initiated with 1,840 patients in each trial with a total of 3,680 patients 3 mg 7 mg R 3 mg 7 mg 1:1 Week 0 4 14 mg oral semaglutide QD 14 mg placebo QD Treatment period 104 14 mg oral semaglutide QD 14 mg placebo QD ↑ Confirmatory endpoints 156 Follow-up 161 Objective To confirm superiority of oral semaglutide vs placebo on the change in cognition and function in people with early Alzheimer's disease Primary endpoint Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score from baseline to end of 104 weeks of treatment Inclusion criteria • . Early Alzheimer's disease (mild cognitive impairment or mild dementia) Mini-Mental State Examination (MMSE) ≥ 22/30 Age between 55-85 years evoke + has at least 20% with small vessel pathology AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; QD: once-daily. Note: CDR-SB ratings are utilising in six domains are summed to provide a clinical measure = Sum of Boxes. These are: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care. CDR-SB Scores range from 0 to 18 with higher scores representing greater impairment CMD22 CAPITAL MARKETS DAY

View entire presentation